Open AccessComparative Economic Outcomes in Patients with Focal Seizure Initiating First-Line Eslicarbazepine Acetate Monotherapy versus Generic Antiseizure Drugs
Author(s) -
Darshan Mehta,
Matthew Davis,
Andrew J. Epstein,
Brian Wensel,
Todd Grinnell,
G. Rhys Williams
Publication year - 2021
Publication title -
clinicoeconomics and outcomes research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.591
H-Index - 27
ISSN - 1178-6981
DOI - 10.2147/ceor.s303079
Subject(s) - medicine , medical prescription , emergency department , retrospective cohort study , pediatrics , emergency medicine , psychiatry , pharmacology
To examine the association between initiating first-line (1L) monotherapy with eslicarbazepine acetate (ESL) vs a generic antiseizure drug (ASD) and healthcare resource utilization (HCRU) and charges in adults with treated focal seizures (FS).